← SynDRA

NILOTINIB

SynDRA canonical compound SYN0008885 — structure-anchored drug synonym record

All known targets

• ABL1
• KIT
• BCR
• DDR1
• DDR2
• PDGFRA
• ABCG2
• MAPK10
• MAP4K1
• MAP2K5
• LYN
• LCK

Mechanisms of action (all sources)

• Abl kinase inhibitor
• ABL1 INHIBITOR
• Tyrosine-protein kinase ABL inhibitor
• DDR1 INHIBITOR
• DDR2 INHIBITOR
• Bcr-Abl kinase inhibitor
• Modulator

Drug classes

• Bcr-Abl Tyrosine Kinase Inhibitors
• Kinase Inhibitor
• Cytochrome P450 2D6 Inhibitors
• P-Glycoprotein Inhibitors
• Cytochrome P450 2C8 Inhibitors
• Cytochrome P450 2C8 Inducers
• Cytochrome P450 2B6 Inducers
• UGT1A1 Inhibitors
• Tyrosine Kinase Inhibitors

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 644241
• ChEMBL: CHEMBL255863
• DrugBank: DB04868
• ChEBI: CHEBI:52172
• KEGG: D06413
• RxNorm: 662281
• PDB: NIL
• Wikipedia: Nilotinib
• TTD: D00STL
• LINCS BRD: BRD-K81528515

Synonyms

• nilotinib hydrochloride hydrate
• tasigna
• nilotinib hydrochloride monohydrate
• AMN-107
• AMN107
• NSC-747599
• NIL
• Nilotinibum
• Tasigna (Novartis)
• Nilotinib (INN/USAN)
• Nilotinib, AMN107, Tasigna
• Tasigna, AMN-107, Nilotinib
• L-1-yl)-3-(trifluoromethyl)phenyl]benzamide
• Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI)
• 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo
• 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
• 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide
• 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
• Nilotinib (BCR-ABL inhibitor 2nd gen)
• Tasigna
• Nilotinib free base
• Nilotinib (AMN-107)
• 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide
• MFCD09833716
• 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
• NSC 747599
• CHEMBL255863
• 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide
• 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide
• CHEBI:52172
• 641571-10-0 (free base)
• NSC747599
• 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide
• F41401512X
• 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide
• benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-
• Nilotinib & its intermediates
• nilotinibum

Reported adverse events

• Sudden death
• QT interval
• Abdominal pain
• Abdominal pain upper
• Alopecia
• Arthralgia
• Asthenia
• Back pain
• Bone pain
• Constipation
• Cough
• Death